| Sep 11 |
J&J mid-stage trial for lung cancer drug Rybrevant hits main goal
|
| Sep 11 |
J&J leads $50M financing for imaging company Spectrawave
|
| Sep 11 |
2 Stocks That Are Passive Income Machines to Buy and Hold Forever
|
| Sep 11 |
Johnson & Johnson reports data from Phase II NSCLC treatment trial
|
| Sep 10 |
Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)
|
| Sep 10 |
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
|
| Sep 10 |
Xencor Stock Gains 23% on Encouraging Pipeline Advancements
|
| Sep 10 |
Kenvue Set To Pop Like A Tylenol Gelcap? Golden Cross Looms On Stock Chart
|
| Sep 9 |
J&J Rybrevant/Lazcluze study shows superiority over Tagrisso
|
| Sep 9 |
J&J’s Rybrevant combo for NSCLC remains better than SOC after three years
|
